Abiopharma

News list

Director Wei Binxian 🟢 acquired 18.8K shares (1 derivative) of PALISADE BIO, INC. (PALI) Transaction Date: Sep 04, 2025 | Filing ID: 012692

Full text

News bot Sept. 5, 2025, 1:01 p.m.
🔍 Wei Binxian (Director)

Company: PALISADE BIO, INC. (PALI)

Report Date: 2025-09-04
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 18,800
Detailed Transactions and Holdings:
- Acquired 18,800 shares of Phantom Units (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 18,800.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
Footnotes:
- F1: Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock.
- F2: The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
- F3: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date.